HEMO+
Available licenses
Oral medication to treat hemophila
Linksium Contact
Laurène El Bahhaj
+33 (0)7 76 23 29 19 laurene.elbahhaj@linksium.fr
Benefits
- Oral administration
- Better quality of life for patients
- Low cost
Key words
- Hemophilia
- Molecule repositioning
- Oral administration
Intellectual Property
- 1 patent
Laboratory
- DPM
Institutions
- CNRS
- UGA
Linksium Continuum
- Maturation
- Commercialization
Results
- Available licenses
Context
Hemophilia is a rare disease due to a deficiency of clotting factor FVIII or FIX depending on whether it is hemophilia A or B. Usually, patients are treated with injection replacement therapy, which generates resistance in approximately 30% of patients.
Technology
We offer the first orally administrable chemical drug based on a repositioning approach.
Advantages
It is a non-invasive, inexpensive treatment that presents little risk of generating antibodies and therefore resistance.
State of progress
Following a screening of existing molecules, a hit has been identified for the coagulation of hemophilia plasma and an optimization work by structural analogy is in progress.
Applications
This treatment would target all types of hemophilia.
Close projects index